u 69593 has been researched along with nifedipine in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Duncan, MJ; Elde, RP; Gurwell, JA; Hauser, KF; Maderspach, K; Stiene-Martin, A | 1 |
| Wang, HX; Wong, TM; Xia, Q; Zhang, WM | 1 |
| Ahmed, MS; Cemerikic, B; Zamah, R | 1 |
5 other study(ies) available for u 69593 and nifedipine
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
kappa-opioid receptor expression defines a phenotypically distinct subpopulation of astroglia: relationship to Ca2+ mobilization, development, and the antiproliferative effect of opioids.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics; Animals; Astrocytes; Benzeneacetamides; Bromodeoxyuridine; Calcium; Calcium Channel Blockers; Cell Count; Cell Division; Cells, Cultured; DNA; Enzyme Inhibitors; Gene Expression Regulation, Developmental; Immunohistochemistry; Mice; Mice, Inbred ICR; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Nifedipine; Phenotype; Pyrrolidines; Receptors, Opioid, kappa; Thapsigargin; Time Factors | 1996 |
Inhibition of [3H]-U69593 binding and the cardiac effects of U50, 488H by calcium channel blockers in the rat heart.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Antihypertensive Agents; Benzeneacetamides; Calcium; Calcium Channel Blockers; Heart; In Vitro Techniques; Male; Nifedipine; Protein Binding; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Tritium; Verapamil | 1997 |
Identification of L-type calcium channels associated with kappa opioid receptors in human placenta.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Benzeneacetamides; Calcium Channel Agonists; Calcium Channel Blockers; Calcium Channels; Calcium Signaling; Cell Membrane; Chorionic Gonadotropin; Chorionic Villi; Culture Techniques; Egtazic Acid; Female; Humans; Isradipine; Naltrexone; Nifedipine; Placenta; Pyrrolidines; Receptors, Opioid, kappa; Trophoblasts | 1998 |